Agtech Appoints Leading Harvard Trained Medical Expert as Chief Science Officer

Rhea-AI Summary

Agtech Global International, Inc. (OTC Pink: AGGL) has appointed Dr. Malcolm A. Leissring as Chief Science Officer effective January 1, 2022. This comes after Agtech's recent agreement to acquire NooMeds, LLC, which markets the dietary supplement A.L.Z. Defense™ aimed at preventing memory issues associated with Alzheimer's disease. Dr. Leissring, an award-winning neuroscientist with a strong background in Alzheimer's research, will direct the company's research and drug development efforts, focusing on psilocybin and CBD formulations.

Positive

• Appointment of Dr. Malcolm A. Leissring as Chief Science Officer brings expertise in Alzheimer's research.
• Acquisition of NooMeds, LLC to market A.L.Z. Defense™, a supplement targeting memory problems.

Negative

• Concerns about the continuity in leadership and potential experience gaps in the company.

CALIFORNIA, Newport Beach, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Agtech Global International, Inc. (Agtech) (name change to Galexxy Holdings Inc. in process) (OTC Pink: AGGL) is pleased to announce the appointment of Dr. Malcolm A. Leissring as its Chief Science Officer (CSO) effective January 1, 2022. This appointment follows Agtech’s recent agreement to acquire NooMeds, LLC., a company formed by Dr. Leissring to market A.L.Z. Defense™, a scientifically tested dietary supplement shown to prevent memory problems in laboratory models of Alzheimer’s disease.

Dr. Leissring is an award-winning neuroscientist who is internationally recognized for his work on the molecular pathogenesis of Alzheimer’s disease and diabetes, with an emphasis on drug discovery and development.  He conducted his postdoctoral training at Harvard Medical School in the laboratory of Dennis J. Selkoe, M.D., one of the world’s leading researchers in Alzheimer’s disease.  

His research has been funded by grants from the National Institutes of Health (NIH) and numerous private foundations. For his pioneering work on Alzheimer’s disease and diabetes, Dr. Leissring has received awards from many prestigious organizations, such as the Alzheimer’s Association, the Ellison Medical Foundation, the American Federation for Aging Research and the American Diabetes Association.  Dr. Leissring was recently awarded a $3 million grant from the NIH’s National Institute on Aging to continue his research on Alzheimer’s disease at the University of California, Irvine.  

In his role as CSO of Agtech/Galexxy, Dr. Leissring will help direct the research and drug development program for the novel compounding of psilocybin and cannabidiol (CBD) into proprietary formulations. This program is being conducted by KRTL Biotech, Inc. in South Korea.

Dr. Leissring added, “I’m excited by this KRTL drug development opportunity to help formally evaluate the therapeutic potential of highly promising compounds that have been in use for millennia, but have been off limits to investigators until only recently.” 

Agtech is publicly traded on the OTC Markets (OTC Pink: AGGL). Headquartered in Newport Beach, California, Agtech is entering the rapidly developing markets for premium CBD consumer products through its recent acquisition of Galexxy Corporation and its joint venture with City Farm Industries. Agtech’s “soil-to-sale” business strategy is keenly focused on controlling the supply chain and maximizing profits.

Agtech Global International, Inc.
Ross Lyndon-James
E: ross@galexxy.com
M: (949) 456 3972

Forward-Looking Information

This press release contains “forward-looking information” and “forward-looking statements” (collectively, “statements”). All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this press release.

https://twitter.com/AgtechGlobal                                   
https://www.krtlbiotech.com
http://galexxyholdings.com.dream.website

Attachment

• $AGGL - Agtech Appoints Leading Harvard Trained Medical Expert as Chief Science Officer

FAQ

Who is Dr. Malcolm A. Leissring and what is his role at AGGL?

Dr. Malcolm A. Leissring is an award-winning neuroscientist appointed as Chief Science Officer of Agtech Global International (AGGL) effective January 1, 2022.

What is the significance of the acquisition of NooMeds, LLC by AGGL?

The acquisition is aimed at marketing the dietary supplement A.L.Z. Defense™, which is designed to help prevent memory problems associated with Alzheimer's disease.

How will Dr. Leissring's appointment impact AGGL?

Dr. Leissring's expertise is expected to enhance AGGL's research and drug development initiatives, particularly in innovative formulations.

What research projects will Dr. Leissring oversee at AGGL?

He will direct research focusing on the compounding of psilocybin and CBD into proprietary formulations.

What are the future plans for AGGL following Dr. Leissring's appointment?

AGGL plans to enter rapidly developing CBD markets and enhance its supply chain control through strategic acquisitions.